Literature DB >> 2397577

Sinus and atrioventricular nodal distribution of sympathetic fibers that contain neuropeptide Y.

M R Warner1, M N Levy.   

Abstract

Neuropeptide Y and norepinephrine are localized in sympathetic nerve terminals throughout the heart. We sought to determine the functional distribution of the neuropeptide Y-containing sympathetic fibers to the sinus and atrioventricular (AV) nodal regions. We recorded cycle length, AV interval, and arterial pressure in 14 anesthetized dogs. We assessed the release of neuropeptide Y from sympathetic nerve terminals by measuring the attenuation of the vagal effects on cycle length and AV interval that occurred after unilateral ansa subclavia stimulation. Three-minute trains of right or left ansa stimulation, each applied at frequencies of 2, 5, and 10 Hz, produced a frequency-dependent inhibition of the vagal effects on cycle length and AV interval. After right ansa stimulation (10 Hz), however, the percent inhibition of the vagal effects on cycle length was 21 +/- 5% greater (p less than 0.001) than the percent inhibition of the vagal effects on AV interval. Conversely, after left ansa stimulation (10 Hz), the percent inhibition of the vagal effects on AV interval was 54 +/- 7% greater (p less than 0.001) than the percent inhibition of the vagal effects on cycle length. The vagal stimulus characteristics (frequency or voltage) did not significantly alter the percent inhibition, nor did the percent inhibition depend on the vagus stimulated (right or left vagus). We conclude that most of the neuropeptide Y-containing sympathetic fibers at the sinus node originate in right-sided ganglia, whereas most of those at the AV node originate in left-sided ganglia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397577     DOI: 10.1161/01.res.67.3.713

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm.

Authors:  Jonathan Buber; Michael Glikson; Michael Eldar; David Luria
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-10       Impact factor: 1.468

2.  Postmortem changes in the immunohistochemical demonstration of nerves in human ventricular myocardium.

Authors:  L T Chow; W H Chow; J C Lee; S S Chow; R H Anderson; J A Gosling
Journal:  J Anat       Date:  1998-01       Impact factor: 2.610

Review 3.  Substrates and potential therapeutics of ventricular arrhythmias in heart failure.

Authors:  Dongze Zhang; Huiyin Tu; Michael C Wadman; Yu-Long Li
Journal:  Eur J Pharmacol       Date:  2018-06-27       Impact factor: 4.432

Review 4.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

5.  Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission.

Authors:  A P Serone; C E Wright; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Innervation of the human cardiac conduction system at birth.

Authors:  L T Chow; S S Chow; R H Anderson; J A Gosling
Journal:  Br Heart J       Date:  1993-05

7.  The innervation of the human myocardium at birth.

Authors:  L T Chow; S S Chow; R H Anderson; J A Gosling
Journal:  J Anat       Date:  1995-08       Impact factor: 2.610

Review 8.  Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation--tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure.

Authors:  Kieran E Brack; James Winter; G André Ng
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

9.  The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.

Authors:  Neil Herring; James Cranley; Michael N Lokale; Dan Li; Julia Shanks; Eric N Alston; Beatrice M Girard; Emma Carter; Rodney L Parsons; Beth A Habecker; David J Paterson
Journal:  J Mol Cell Cardiol       Date:  2011-12-07       Impact factor: 5.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.